• Alkermes Inc., of Cambridge, Mass., said it consummated its exchange with, and cash offer to, the holders of its 3.75 percent convertible subordinated notes due 2007. Alkermes issued $174.6 million aggregate principal amount of new notes, which represented $114.6 million of new notes issued in exchange for existing notes tendered in the exchange offer and $60 million of new notes sold for cash to holders of existing notes who participated in the exchange offer.

• Xtrana Inc., of Broomfield, Colo., is being sued by Trinity Biotech plc, of Dublin, Ireland, which alleged breach of contract, breach of the implied covenant of good faith and fair dealing, fraud, negligent misrepresentation, unjust enrichment, and violation of the Delaware Consumer Fraud Act in conjunction with Xtrana's sale of its hemostasis business to Trinity. Xtrana divested its hemostasis business by selling substantially all of the assets of that business for $6.25 million plus the assumption of certain liabilities. Trinity's lawsuit alleges that Xtrana misrepresented the status of a single Xtrana product that was the subject of a patent infringement lawsuit at the time of the sale. Trinity is seeking $1.2 million in damages, and $3 million in punitive damages.